Literature DB >> 26379864

Rapamycin, an mTOR inhibitor, induced apoptosis via independent mitochondrial and death receptor pathway in retinoblastoma Y79 cell.

Yan-Dong Wang1, Yong-Jing Su2, Jian-Ying Li2, Xiang-Chao Yao1, Guang-Jiang Liang1.   

Abstract

Rapamycin is helpful in the treatment of certain cancers by inhibiting mTOR (mammalian target of rapamycin) pathway. Here, rapamycin mediated apoptosis were investigated in human retinoblastoma Y79 cells. The MTT assay showed that the IC50 value of rapamycin against Y79 cells was 0.136 ± 0.032 μmol/L. Flow cytometry analysis indicated that the percentage of apoptotic cells was increased from 2.16 ± 0.41% to 12.24 ± 3.10%, 20.16 ± 4.22%, and 31.32 ± 5.78% after 0.1, 0.2, and 0.4 μmol/L rapamycin or without rapamycin treatment for 48 hours. Flow cytometry analysis showed that rapamycin induced mitochondrial membrane potential (∆Ψm) collapse in Y79 cells in a concentration-dependent manner. Western blot assay showed that rapamycin led to release of cytochrome c from mitochondrial membranes to cytosol. Further Western blot assays showed that rapamycin induced activation of caspase-9 and caspase-8 and the cleavage of caspase-3. Rapamycin induced cleavages of caspase-3 and apoptosis was inhibited by both Z-LETD-FMK and Z-IETD-FMK treatment. Together, all these results illustrated that rapamycin induced apoptosis in human retinoblastoma Y79 cells involvement of both intrinsic and extrinsic pathways.

Entities:  

Keywords:  Retinoblastoma; extrinsic apoptosis signaling pathway; intrinsic apoptosis signaling pathway; rapamycin

Year:  2015        PMID: 26379864      PMCID: PMC4565247     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  33 in total

Review 1.  Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.

Authors:  Seth A Wander; Bryan T Hennessy; Joyce M Slingerland
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

Review 2.  PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.

Authors:  Lise Willems; Jerome Tamburini; Nicolas Chapuis; Catherine Lacombe; Patrick Mayeux; Didier Bouscary
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

Review 3.  Models and discovery strategies for new therapies of retinoblastoma.

Authors:  Samuel K Houston; Theodore J Lampidis; Timothy G Murray
Journal:  Expert Opin Drug Discov       Date:  2013-02-22       Impact factor: 6.098

Review 4.  Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

Authors:  James J Gibbons; Robert T Abraham; Ker Yu
Journal:  Semin Oncol       Date:  2009-12       Impact factor: 4.929

Review 5.  Current management strategies for intraocular retinoblastoma.

Authors:  Jonathan W Kim; David H Abramson; Ira J Dunkel
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 6.  Retinoblastoma: review of current management.

Authors:  Murali Chintagumpala; Patricia Chevez-Barrios; Evelyn A Paysse; Sharon E Plon; Richard Hurwitz
Journal:  Oncologist       Date:  2007-10

7.  Triterpenoid pristimerin induced HepG2 cells apoptosis through ROS-mediated mitochondrial dysfunction.

Authors:  Yan Guo; Wei Zhang; Yan-Yan Yan; Cun-Gen Ma; Xia Wang; Chen Wang; Jia-Li Zhao
Journal:  J BUON       Date:  2013 Apr-Jun       Impact factor: 2.533

8.  Brazilein, a compound isolated from Caesalpinia sappan Linn., induced growth inhibition in breast cancer cells via involvement of GSK-3β/β-Catenin/cyclin D1 pathway.

Authors:  Li-yang Tao; Jian-ying Li; Jian-ye Zhang
Journal:  Chem Biol Interact       Date:  2013-08-13       Impact factor: 5.192

9.  A mammalian protein targeted by G1-arresting rapamycin-receptor complex.

Authors:  E J Brown; M W Albers; T B Shin; K Ichikawa; C T Keith; W S Lane; S L Schreiber
Journal:  Nature       Date:  1994-06-30       Impact factor: 49.962

Review 10.  Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis.

Authors:  Alberto Ocana; Francisco Vera-Badillo; Mustafa Al-Mubarak; Arnoud J Templeton; Verónica Corrales-Sanchez; Laura Diez-Gonzalez; María D Cuenca-Lopez; Bostjan Seruga; Atanasio Pandiella; Eitan Amir
Journal:  PLoS One       Date:  2014-04-28       Impact factor: 3.240

View more
  4 in total

Review 1.  Molecular signaling cascades involved in nonmelanoma skin carcinogenesis.

Authors:  Robert P Feehan; Lisa M Shantz
Journal:  Biochem J       Date:  2016-10-01       Impact factor: 3.857

2.  Inhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin.

Authors:  Sally E Dickinson; Jaroslav Janda; Jane Criswell; Karen Blohm-Mangone; Erik R Olson; Zhonglin Liu; Christy Barber; Emanuel F Petricoin; Valerie S Calvert; Janine Einspahr; Jesse E Dickinson; Steven P Stratton; Clara Curiel-Lewandrowski; Kathylynn Saboda; Chengcheng Hu; Ann M Bode; Zigang Dong; David S Alberts; G Timothy Bowden
Journal:  Cancer Prev Res (Phila)       Date:  2016-01-22

3.  Amelioration of Diabetic Nephropathy by Targeting Autophagy via Rapamycin or Fasting: Relation to Cell Apoptosis/Survival.

Authors:  Khaled Gouda; Sherihan AbdelHamid; Ahmed Mansour; Nesreen Omar; Hala El-Mesallamy
Journal:  Curr Issues Mol Biol       Date:  2021-10-22       Impact factor: 2.976

4.  Mechanism study of isoflavones as an anti-retinoblastoma progression agent.

Authors:  Qifeng Wu; He Bai; Chu-Long Huang; Yongming Zhang; Xiayun Zeng; Huan Wan; Wen Zuo; Hai-Ying Wang; Yi-Xin Zeng; Yan-Dong Wang
Journal:  Oncotarget       Date:  2017-07-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.